Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What is the Anticipated CAGR of the Minimal Residual Disease Market, and What Factors Will Drive It?
The market size of minimal residual disease has been burgeoning in recent times. From being evaluated at $1.78 billion in 2024, it is predicted to escalate to $2.01 billion in 2025, showcasing a compound annual growth rate (CAGR) of 12.9%. The aforementioned surge during the historical period is linked with factors such as the augmenting count of cancer patients, growing expenditure on research & development, enhanced accessibility of healthcare, an increasing occurrence of blood cancer, and a surge in public awareness.
The market size for minimal residual disease is predicted to experience a swift surge in the coming years and is estimated to expand to $3.22 billion by 2029 with a compound annual growth rate of 12.5%. Multiple factors will contribute to this predicted growth within the projected period including an increasing cancer patient count, elevated awareness efforts by the government, improvements in healthcare affordability, rising per capita income in developing economies, and government-led initiatives to raise cancer awareness. Trends that are anticipated to prevail during the forecast period encompass the advancement of next-generation sequencing technology, normalization of MRD testing, personalized MRD monitoring adoption, advancements in liquid biopsy methodologies, and treatment focusing on minimal residual disease.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21224&type=smp
What Are the Primary Drivers Supporting the Market Growth of the Minimal Residual Disease Market?
The escalating incidence of cancer is projected to fuel the expansion of the minimal residual disease market in the future. Cancer refers to a collection of diseases marked by uninhibited growth and distribution of abnormal cells within the body. The surge in cancer incidence can be attributed to elements such as an aging demographic, greater exposure to environmental carcinogens, unhealthy ways of living, and genetic predispositions. The increased occurrence of cancer heightens the need for accurate MRD testing to identify remaining cancer cells, facilitating early action and tailored treatment. This enhances the forecast of relapse and improves the results for patients. For example, as reported by the National Cancer Institute (NCI), a government agency in the United States, in May 2024, there were approximately 20 million new cancer cases and 9.7 million cancer-induced deaths globally in 2022. The estimates for 2040 indicate 29.9 million fresh cases and 15.3 million cancer-related fatalities. Thus, the escalating incidence of cancer is a significant factor contributing to the expansion of the minimal residual disease market.
Which Primary Segments of the Minimal Residual Disease Market Are Driving Growth and Industry Transformations?
The minimal residual disease market covered in this report is segmented –
1) By Detection Target: Lymphoma, Leukemia, Solid Tumors, Other Detection Targets
2) By Test Technique: Flow Cytometry, Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Other Test Techniques
3) By End-User: Banking, Financial Services, And Insurance (BFSI), Retail And E-Commerce, Hospitals, Diagnostic Laboratories, Research Institutions
Subsegments:
1) By Lymphoma: Hodgkin Lymphoma, Non-Hodgkin Lymphoma
2) By Leukemia: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia
3) By Solid Tumors: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer
4) By Other Detection Targets: Multiple Myeloma, Neuroblastoma, Sarcomas
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21224&type=smp
Which Regions Are Key Players in the Growth of the What Are the Primary Drivers Supporting the Market Growth of the Minimal Residual Disease Market? Market?
North America was the largest region in the minimal residual disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the minimal residual disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Most Significant Market Trends in the Minimal Residual Disease Market?
Key players in the minimal residual disease (MRD) market are focusing on the creation of advanced In Vitro Diagnostic (IVD) testing services. These services aim to offer bespoke therapy options that will improve patient results. Specifically, an In Vitro Diagnostic (IVD) test service can identify remaining cancer cells following treatment in a lab setting, enabling the prediction of recurrence and refinement of therapeutic strategies. For example, Adaptive Biotechnologies Corporation, a biotechnology firm based in the US, launched clonoSEQ Assay in December 2022. This test was designed to detect MRD in patients with diffuse large B-cell lymphoma (DLBCL) by examining circulating tumor DNA (ctDNA) in blood samples. This approach allows for a non-invasive, highly sensitive way to observe cancer progression and early signs of a relapse. This assay gives medical professionals a more detailed view of a patient’s disease load, assisting them in creating tailored treatment plans. This is the first MRD test for DLBCL to be covered by Medicare, bringing it into wide accessibility for all treatment schedules and time points.
View the full report here:
https://www.thebusinessresearchcompany.com/report/minimal-residual-disease-global-market-report
What Parameters Are Used to Define the Minimal Residual Disease Market?
Minimal residual disease (MRD) refers to the few cancer cells that persist in the body after treatment, despite clinical remission. Monitoring minimal residual disease (MRD) helps detect early signs of relapse, evaluate treatment effectiveness, and predict the risk of recurrence. This sensitive detection can guide tailored therapies to improve outcomes and reduce the likelihood of relapse.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21224
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model